ArticleFrontiers in cardiovascular medicine2026
From acute diagnosis to longitudinal risk stratification: a paradigm shift in the clinical role of cardiac biomarkers.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This perspective examines the evolving role of cardiac biomarkers from acute diagnostic tools to integral components of longitudinal risk stratification and cardiovascular disease management. Evidence from cohort studies, clinical trials, and high-sensitivity assays demonstrates that biomarkers reflecting myocardial injury, hemodynamic stress, inflammation, fibrosis, and metabolic dysfunction can inform prevention, early detection, acute care, and chronic monitoring. Key implementation strategies include multi-biomarker panels, serial measurements, multi-omics integration, and artificial intelligence-based risk modeling. Challenges such as assay standardization, clinical interpretation, and cost-effectiveness are critically evaluated. Overall, this framework highlights the potential for biomarker-guided approaches to promote more preventive, precise, and patient-centered cardiovascular care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.